GRI Bio Announces Exercise of Warrants
October 21, 2024 17:35 ET
|
GRI Bio, Inc.
LA JOLLA, CA, Oct. 21, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell...
GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series
July 15, 2024 09:05 ET
|
GRI Bio, Inc.
Live video webcast on Wednesday, July 17th at 12:00 PM ET LA JOLLA, CA, July 15, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio,” “we,” “our,” or the “Company”), a...
GRI Bio Announces Partnership with the Respiratory Translational Research Collaboration to Advance Leading NKT Regulation Technology Targeting Earlier in the Inflammatory Cascade to Modulate Disease Progression
October 17, 2023 08:35 ET
|
GRI Bio, Inc.
UK consortia brings together internationally recognized investigators in the UK's leading centers of excellence to carry out experimental and early phase research Translational work to be...
Vallon Pharmaceuticals and GRI Bio Enter into Merger Agreement with Goal of Advancing Innovative Pipeline of NKT Cell Regulators
December 13, 2022 16:05 ET
|
Vallon Pharmaceuticals Inc.
Combined company will operate as GRI Bio and advance innovative pipeline of Natural Killer T (NKT) regulating therapies for the treatment of inflammatory, fibrotic and autoimmune diseases GRI...